Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067470 · ClinicalTrials.gov registry record · Phase 3
Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI
A Phase 3 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT00067470 is a Phase 3 study that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 39 participants.
The verdict
NCT00067470, a Phase 3 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the ability of rhASB versus placebo to enhance endurance in patients with Mucopolysaccharidosis VI (MPS VI), as evidenced by an increase in the number of meters walked in the 12 minute walk test at Week 24 compared with baseline.
Interventions
- DRUG Placebo
- DRUG N-acetylgalactosamine 4-sulfatase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2003-09 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067470
The ClinicalTrials.gov registry entry for NCT00067470 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00067470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067470 about?
NCT00067470 is a clinical study titled "Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI". The purpose of the study is to evaluate the ability of rhASB versus placebo to enhance endurance in patients with Mucopolysaccharidosis VI (MPS VI), as evidenced by an increase in the number of meters walked in the 12 minute walk test at Week 24 compared with baseline.
What is the current status of trial NCT00067470?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2003-09. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00067470?
The interventions under investigation include: Placebo (DRUG), N-acetylgalactosamine 4-sulfatase (DRUG).
Who is sponsoring clinical trial NCT00067470?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.